THRIVE I: Efficacy and tolerability of the novel, oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis. Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Schulman, Sam
  • Wahlander, K
  • Gustafsson, D
  • Welin, L
  • Frison, L
  • Eriksson, H

publication date

  • November 16, 2001

published in